Drug Profile
PF 614
Alternative Names: BIO-MD™ PF614; ER Oxycodone - Ensysce Biosciences; ER Oxycodone Bio-MD™ System; Oxycodone prodrug extended release - Ensysce Biosciences; PF614; PF614 MPAR™; PF614-TAAP™; PRF 06014; PRF-06104Latest Information Update: 11 Oct 2023
Price :
$50
*
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pain
Most Recent Events
- 11 Oct 2023 Phase-II clinical trials in Pain (In volunteers) in USA (PO)
- 10 Sep 2023 Pharmacokinetics data from phase-Ib trial in Pain presented at the 2023 American College of Clinical Pharmacology Annual Meeting (ACCP-2023)
- 12 Jul 2023 Pharmacokinetics data from phase-Ib trial in Pain (In volunteers) released by Ensysce Biosciences (Ensysce Biosciences website- July 2023)